Tamsulosin Hydrochloride Capsule
Product Images NDC 72162-2509

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 72162-2509). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721622509)

Each capsule contains Tamsulosin Hydrochloride USP 0.4 mg. The usual dosage instructions and prescribing information can be found in the package insert. Store the capsules at a temperature of 20° to 25°C (68° to 77°F), avoiding excessive moisture. They must be dispensed in a tight container and kept out of reach of children. This product, containing 100 capsules, is relabeled by Bryant Ranch Prepack, Inc. and manufactured by Aurobindo Pharma Limited.*

FDA Label Image

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin Fig1)

This text provides information on the mean plasma concentration of Tamsulosin Hydrochloride following the administration of 0.4 mg capsules under both fasted and fed conditions. The concentration data is likely presented graphically in Figure 1 over a period of time in hours.*

FDA Label Image

Figure 2a Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin Fig2)

Figure 2A shows the mean change from baseline in Total AUA Symptom Score (on a scale of 0 to 35) for Study 1. The figure compares the treatment groups with tamsulosin 0.08mg, alfuzosin 10mg, and placebo over a duration of weeks. The data includes the number of participants for each treatment group at different time points.*

FDA Label Image

Figure 2b Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin Fig3)

This is a statistical data related to the treatment with different doses of LNt (0.08mg to 0.4mg) and placebo in Study 2, showing the mean change from baseline in the Total AUA Symptom Score over a duration of treatment in weeks.*

FDA Label Image

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin Fig4)

This is a study evaluating the mean increase in peak urine flow rate for different treatments over a specified duration in weeks. The results are presented in Figure 3A and include the treatments of 25mg, 0.08mg, 2x0.4mg, and Placebo. The study involved a significant number of participants across different treatment groups.*

FDA Label Image

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin Fig5)

The text provides information about the Mean Increase in Peak Urine Flow Rate (mL/Sec) in Study 2, specifically dealing with different treatment options and the Duration of Treatment in weeks. The data seems to be related to a scientific study on urinary flow rates.*

FDA Label Image

Chemical Structure (Tamsulosin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.